Booming interest in targeted chemotherapy continues with Genmab's $1.8B acquisition of ProfoundBio

Biotechs focused on antibody-drug conjugates are getting scooped up by larger pharma companies.

April 5, 2024 Check out STAT+

Sponsored By

Drew Angerer/Getty Images STAT+ | Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies The $1.8 billion deal is the latest acquisition centered on antibody-drug conjugates, which deliver chemotherapies directly to tumor sites. By Andrew Joseph STAT+ | Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market Cyltezo can be substituted for Humira at the pharmacy counter without a doctor's permission, yet PBMs have been slow to adopt it. By John Wilkerson STAT+ | Matt & Adam's Take: Amylyx did the right thing by withdrawing its ALS drug. That's rare and worthy of praise The company's co-CEOs had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit. By Adam Feuerstein and Matthew Herper Adobe Opinion: For national security, the U.S. must maintain its biotech dominance How America maintains and extends its current advantage in biotech innovation may well determine the country's future. By John F. Crowley

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser